It is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3e7cKQi
via IFTTT
Biosimilar drugs can help us reach $1 billion target soon: Christiane Hamacher, CEO, Biocon Biologics
It is all about reaching our $1billion revenue target by FY22 and to reach 5 million patients by end of 2022, says Christiane Hamacher.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3e7cKQi
via IFTTT
0 comments:
Post a Comment